Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
B M BonoraA AvogaroGian Poalo FadiniPublished in: Acta diabetologica (2019)
Treatment with ELAR does not increase the risk of cardiovascular events and may reduce all-cause mortality.